Trypanosoma cruzi infection: strategies for the development of a vaccine

Authors

DOI:

https://doi.org/10.56294/piii2024351

Keywords:

Chagas disease, Trypanosoma Cruzi, vaccines, trans sialidase

Abstract

Background: The Chagas-Mazza disease is an infection caused by the protozoan Trypanosoma cruzi and is considered one of the main public health problems in America. Because a large number of wild animals are T. cruzi reservoir, the lack of health policies for prevention and the lack of a vaccine, the infection cannot be eradicated. There are currently no vaccines against this Chagas disease, its development and application would be essential for the control of infection. Material and methods: A systematic review of study publications is carried out and metanalysis is carried out that integrates all available public information on the subject of study. 
 Results:  Over the years, a wide variety of vaccine platforms against Chagas-Mazza's disease have been investigated. The protection against the disease could be achieved by an mTS formulation plus a protein adjuvant. A recombinant protein derived from TS (TSr) together with the adjuvant CpG (TLR-9 agonist) was administered both intramuscular and intranasal with very good results. The glycosylated mutant trans-sialidase (TSm) formulation together with the adjuvant iscomatrix is highly effective, it reduces parasitemia by 50%. The nasal administration of Transpaine plus c-di-AMP is a highly immunogenic formulation that contributes to the control of the parasites, presenting less clinical evidence of infection and limited side effects. 
 Conclusion: several research carried out so far and the progress made by immunization with vaccines using attenuated or inactivated live antigens or parasites or recombinant proteins in experimental models with promising results for the development of a vaccine in humans

References

Organización Mundial de la Salud. Enfermedad de Chagas (tripanosomiasis americana). OMS; 2023, https://www.who.int/es/news-room/factsheets/detail/chagas-disease-(americantrypanosomiasis).

Molina Israel, Salvador Fernando, Sánchez-Montalva Adrián, “Actualización en enfermedad de Chagas, Enfermedades Infecciosas y Microbiología Clínica”, Volumen 34, Número 2, 2016, Páginas 132-138.

Pérez-Molina, José A. y Pérez-Ayala, Ana y Moreno, Santiago y Fernández-González, M. Carmen y Zamora, Javier y López-Vélez, Rogelio, Uso de benznidazol para tratar la enfermedad de Chagas crónica: una revisión sistemática con un metaanálisis Revista de quimioterapia antimicrobiana, Volumen 64, página 1139-1147, 2009.

Rodríguez-Morales Olivia, Monteón-Padilla Víctor, Carrillo-Sánchez Silvia, Rios-Castro Martha, Martínez-Cruz Mariana, Carabarin-Lima Alejandro, Arce-Fonseca Minerva, “Experimental Vaccines against Chagas Disease: A Journey through History”, Journal of Immunology Research, vol. 2015, Article ID 489758, 8 Pages, 2015.

da Costa KM, Marques da Fonseca L, Dos Reis JS, Santos

MARDC, Previato JO, Mendonça-Previato L, Freire-deLima L. Trypanosoma cruzi trans-Sialidase as a Potential Vaccine Target Against Chagas Disease. Front Cell Infect Microbiol. 2021 oct 26; 11:768450. PMCID: PMC8576188.

Dinatale B, Bulfoni Balbi C, González F B, Pérez A R y Pacini M F. (2020) “Desarrollos preclínicos de vacunas profilácticas contra la Enfermedad de Chagas basadas en Transialidasa” Rev Fac Cs Méd UNR. Vol. 1: pp. 23 a 38.

Augusto E. Bivona, Andrés Sánchez Alberti, Natacha Cerny, Sebastián N. Trinitario, Emilio L. Malchiodi, “Diseño de vacuna contra la enfermedad de Chagas: la búsqueda de un control inmunomediado eficaz contra el

Trypanosoma cruzi”, Biochimica et Biophysica Acta (BBA) –Base molecular de la enfermedad, Volumen 1866, Número 5,2020.

Hoft DF, Eickhoff CS, Giddings OK, Vasconcelos JR, Rodrigues MM “Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic Trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming”. J Immunol. 2007 nov 15;179(10):6889900.

Germán H. Fontanella, Kristof De Vusser, Wouter Laroy, Lucas Daurelio, Ana Lía Nocito, Silvia Revelli, Rolando Contreras, “La inmunización con una trans-sialidasa mutante diseñada protege en gran medida a los ratones de la infección experimental por Trypanosoma cruzi: una vacuna candidata”, Volumen 26, Número 19, 2008, Páginas 2322-2334.

Iván Alejandro Bontempi, Miguel Hernán Vicco, Gabriel Cabrera, Silvina Raquel Villar, Florencia Belén González, Eduardo Angel Roggero, Paul Ameloot, Nico

Callewaert, Ana Rosa Pérez, Iván Sergio Marcipar, “Eficacia de una vacuna candidata de subunidad transsialidasa-ISCOMATRIX para proteger contra la enfermedad de Chagas experimental”, Volumen 33, Número 10, 2015, Páginas 1274-1283.

Duschak G. Vilma y Couto S. Alicia, “Cruzipain, la cisteína proteasa principal de Trypanosoma cruzi: un antígeno glicoproteico sulfatado como candidato relevante para el desarrollo de vacunas y objetivo farmacológico” ... Una revisión, Química medicinal actual 2009; 16 (24).

Sánchez Alberti, A., Bivona, A.E., Cerny, N. et al. “Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection”, npj Vaccines 2, 9 (2017).

Pacini Maria F., Bulfoni Balbi Camila, Dinatale Brenda, Florencia B. González, Estefanía Prochetto, Maria A. De Hernández, Pamela Cribb, Cecilia Farré, Martín Espariz, Víctor S. Blancota, Christian Magni, Marcipar Iván, Ana R. Pérez, “La vacuna intranasal basada en transialidasa contra Trypanosoma cruzi desencadena un perfil mixto de citoquinas en el tejido linfoide asociado a la nasofaringe y confiere inmunogenicidad local y sistémica”, Acta Trópica, Volumen 241, 2023, 106889.

Castro, J.T., Brito, R., Hojo-Souza, N.S. et al. “ASP2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas’ disease. Npj Vaccines 8, 81 (2023).

Ramponi Francesco, Aerts celine, Sartor Paula, Pinazo Maria jesus, Freilij Héctor, Guzmán Carlos A., Malchiodi Emilio, Elisa Sicuri, “Desarrollo de vacunas para la enfermedad de Chagas (CRUZIVAX): preferencias de los actores interesados y posibles impactos en la salud”, Gaceta Sanitaria, Volumen 37, 2023,102275.

de Villasante Fuentes, M., & Pastor, P. H. (2015). “El diagnóstico de la enfermedad de Chagas. Actualización en Medicina de Familia”, 11(3), 141-145.

Downloads

Published

2024-06-12

How to Cite

1.
Siclla Godoy MK, Carnovale SI. Trypanosoma cruzi infection: strategies for the development of a vaccine. SCT Proceedings in Interdisciplinary Insights and Innovations [Internet]. 2024 Jun. 12 [cited 2024 Oct. 7];2:351. Available from: https://proceedings.ageditor.ar/index.php/piii/article/view/316